News

Find News

Filter articles

Applied Filters

Showing 51 to 60 of 121 results

IP strategy chief focus for life sciences counsel, says report

International26-01-2017

Global intellectual property strategy will be the chief area of focus for IP counsel in the life sciences arena in 2017.

WTO amends TRIPS to ease poor countries’ access to medicine

International24-01-2017

The World Trade Organization has amended its intellectual property rules to make it easier for poor countries to access affordable medicines.

Australia should change patent extension approach, says report

Australia23-12-2016

A report released by the Australian government has said Australia's extension of term scheme for patents in the pharmaceutical industry "has had little effect" on investment and innovation.

Phylogica and Genentech extend collaboration for antibiotic research

Australia21-12-2016

Phylogica, an Australian drug discovery company, has extended its research collaboration and licensing agreement with Genentech to discover novel antibiotics.

Mylan enters MPP agreement over affordable hepatitis C generics

International29-11-2016

Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool, a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries.

Sanofi and Genzyme recover domain at WIPO

International16-11-2016

Pharmaceutical company Sanofi and its subsidiary Genzyme have recovered a domain name that infringed a trademark at the World Intellectual Property Organization’s Arbitration and Mediation Center.

Novartis wins growth hormone domain dispute

International20-10-2016

Healthcare company Novartis has won a domain name dispute at the World Intellectual Property Organization Arbitration and Mediation Center.

AstraZeneca to divest Rhinocort Aqua rights outside US

International10-10-2016

AstraZeneca and Cilag, an affiliate of Johnson & Johnson, have entered into an agreement for AstraZeneca to divest the rights to Rhinocort Aqua outside the US.

Teva and Regeneron partner in $250m deal

International22-09-2016

Teva and Regeneron Pharmaceuticals have combined to develop and commercialise fasinumab, a novel nerve growth factor (NGF) antibody.

Australia's drug prices to drop by up to 50%

Australia06-09-2016

More than 2,000 medicine brands treating common conditions will drop in price for millions of Australians from October 1, according to the Australian government’s Department of Health.

Showing 51 to 60 of 121 results

LSIPR